A New Alliance Targets the Root of Degenerative Disease

MUMBAI, India & BASEL, Switzerland – April 20, 2026 – In a move that could redefine the fight against some of humanity's most devastating illnesses, Swiss biotech firm Amporin Pharmaceuticals and Indian chemistry specialist SynSmart Rasayan Research Private Limited have announced a collaboration to develop a new class of drugs for degenerative diseases. The partnership aims to accelerate the creation of therapeutics for conditions like Alzheimer’s, Parkinson’s, and ALS by targeting a fundamental, yet often overlooked, aspect of cellular health: the integrity of the cell membrane.

This international alliance brings together Amporin's cutting-edge scientific platform with SynSmart's agile and efficient chemistry services. Under the agreement, SynSmart will synthesize a vast library of novel molecules designed by Amporin to protect and repair cellular membranes, potentially halting or even reversing the cellular damage that drives these progressive diseases.

Repairing the Cell's First Line of Defense

For decades, the prevailing approach to treating neurodegenerative diseases has focused on clearing the toxic protein aggregates—like amyloid-beta in Alzheimer's—that are hallmarks of these conditions. While important, this strategy has yielded limited success in stopping the diseases' relentless march. Amporin Pharmaceuticals is pioneering a different, more fundamental approach: reinforcing the very walls of the cell.

Emerging research indicates that a key event in the progression of many degenerative diseases is the physical breaching of cell and mitochondrial membranes. Misfolded proteins can form pore-like structures that puncture these vital barriers, leading to a cascade of catastrophic events: uncontrolled ion flow, energy failure in the mitochondria, and ultimately, cell death. Amporin's technology is designed to create small-molecule drugs that act as a microscopic repair crew, plugging these holes and restoring the membrane's integrity. By doing so, these therapies aim to restore normal cellular function and stop the disease at a much earlier and more foundational stage.

"We are excited to form this collaboration with SynSmart as it will accelerate the cross-target screening, optimization and selection of disease-modifying treatments for multiple deadly degenerative diseases in parallel," said Dr. Kelvin Stott, Founder and CEO at Amporin, in the official announcement. This strategy validates the "scope and potential" of Amporin's unique asset platform. The goal is not just to manage symptoms but to develop truly disease-modifying treatments for over 50 different degenerative conditions linked by this common mechanism of membrane damage.

A Global Crisis Seeking a Breakthrough

The urgency for such a breakthrough cannot be overstated. Globally, the number of people living with degenerative diseases is staggering and growing. An estimated 55 million people worldwide live with dementia, a figure projected to soar to 152 million by 2050. The global market for neurodegenerative disease treatments was valued at over $42 billion in 2023 and is expected to more than double to over $90 billion by 2033, reflecting both the immense patient population and the desperate need for effective therapies.

In the United States alone, nearly 90,000 people are diagnosed with Parkinson's each year, while Alzheimer's affects an estimated 7.2 million Americans aged 65 and older. For many of these conditions, the current standard of care offers little more than temporary symptomatic relief. Drugs for Alzheimer's may modestly slow cognitive decline in the early stages, and Parkinson's treatments like levodopa can lose effectiveness and cause debilitating side effects over time. For ALS, existing medications extend survival by only a few months.

This vast unmet medical need has created a landscape where innovative approaches like Amporin's are desperately sought. By shifting the focus from clearing debris to repairing the cellular foundation, the collaboration hopes to open a new therapeutic chapter for millions of patients and their families who currently have few effective options.

A Modern Model for Drug Development

The partnership between Amporin and SynSmart exemplifies a modern, efficient model for pharmaceutical research and development. Amporin, an emerging biotech, possesses the innovative scientific vision and a novel therapeutic platform. However, translating that vision into a library of potential drug candidates requires immense and specialized chemistry resources.

This is where SynSmart, a boutique Contract Research, Development, and Manufacturing Organization (CRDMO), comes in. Based in Mumbai, the company provides the specialized workforce and infrastructure to rapidly synthesize and test the complex molecules Amporin needs. With a team of over 125 chemists and advanced technologies like flow chemistry, SynSmart can produce the substantial library of compounds required for screening, a task that would be prohibitively slow and expensive for a small biotech to undertake alone.

Mr. Saurabh Kapure, CEO at SynSmart, highlighted the strategic advantage this provides. "This collaboration is a testimony of value that SynSmart can bring to the table for its partners," he stated. "With lab operations running in multi-shift mode and lean team hierarchy, the speed and cost-savings help partners get more done for less." This synergy allows Amporin to accelerate its discovery pipeline significantly, moving from theoretical molecules to potential candidates for clinical trials at a pace that traditional R&D models often cannot match.

India's Expanding Role on the Global R&D Stage

Beyond its immediate scientific goals, the SynSmart-Amporin alliance highlights a major shift in the global pharmaceutical landscape. For years, India has been known as the "pharmacy of the world" for its prowess in manufacturing generic drugs. Today, however, the country's role is evolving rapidly. Indian CRDMOs like SynSmart are increasingly becoming high-value partners in the earliest and most complex stages of drug discovery.

This trend is driven by a confluence of factors, including a global push to de-risk supply chains, a large and growing pool of highly skilled scientific talent in India, and significant cost and speed advantages. Western pharmaceutical and biotech companies are no longer just outsourcing manufacturing; they are engaging Indian firms as strategic collaborators in cutting-edge research.

The collaboration to develop breakthrough therapeutics for degenerative diseases is a prime example of this new dynamic. A Swiss firm at the forefront of biotech innovation is entrusting a critical part of its R&D process to an Indian partner, not just for cost savings, but for their specialized expertise and ability to accelerate the project. This partnership underscores India's ascent as a key hub in the global innovation ecosystem, contributing critical capabilities to the quest for new medicines. As this collaboration moves forward, it will be a test case not only for a novel scientific hypothesis but also for a globalized model of drug development that could bring future therapies to patients faster than ever before.